P2X3 Antagonist Composition With Selective P2X2/3 Sparing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for a novel ligand, particularly an antagonist, that selectively targets P2X3 and/or P2X2/3 receptors to treat conditions associated with pain sensitivity and bladder function, as existing methods have limitations in efficacy and selectivity.
Innovation Solution
Development of structurally novel triazinylmethylcycloalkylcarboxylic acid derivatives or their pharmaceutically acceptable salts and stereoisomers, which exhibit high inhibitory activity against P2X3 and low activity against P2X2/3, providing significant inhibitory selectivity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing ligands for P2X3 and P2X2/3 receptors are used, then some level of receptor modulation is achieved, but the inhibitory selectivity between P2X3 and P2X2/3 is insufficient
Solution Approach 1:
The patent applies local quality by introducing specific structural features (triazinylmethylcycloalkylcarboxylic acid derivative structure with specific substituents R1-R6) that create differential binding affinity to P2X3 versus P2X2/3 receptors. The molecular structure includes localized functional groups (carboxylic acid, triazine ring, cycloalkyl) positioned to interact selectively with P2X3 receptor binding sites, achieving high inhibitory selectivity while maintaining P2X3 modulation capability.
2Adaptability or versatility
If broad-spectrum purinergic antagonists are used to block both P2X3 and P2X2/3, then comprehensive receptor coverage is achieved, but specificity for P2X3-mediated functions is lost
Solution Approach 1:
The patent segments the purinergic receptor blocking function by designing compounds that selectively target the P2X3 receptor subtype rather than providing uniform blocking of all purinergic receptors. The molecular structure (formula I) contains specific pharmacophores that recognize P2X3 binding sites, effectively separating P2X3 modulation from P2X2/3 interaction, thus maintaining specificity for P2X3-mediated bladder and pain functions.
3Reliability
If high-affinity P2X3 antagonists are developed, then therapeutic efficacy for bladder and pain conditions is improved, but off-target effects on P2X2/3 may increase
Solution Approach 1:
The patent applies parameter changes by systematically varying molecular parameters (substituents R1-R6, cycloalkyl ring size, triazine substitution patterns) to optimize the balance between P2X3 affinity and P2X2/3 selectivity. The carboxylic acid group (—C(O)OH or —C(O)OR) and its positioning are critical parameters that enhance P2X3 binding while controlling P2X2/3 interaction, achieving high therapeutic efficacy with minimized off-target effects.
Data Source
AI summary
A substituted triazinylmethylcycloalkylcarboxylic acid derivative having a structure as shown in formula (I). In addition, further disclosed are a pharmaceutically acceptable salt, a stereoisomer, a pharmaceutical composition and the use of the derivative. The compound has significant P2X3 inhibitory activity and selectivity, and is high in application value.